Armata Q1 net loss $6.5M, cash $11.7M; AP-SA02 Phase 1b/2a topline due H1 2025

Armata Pharmaceuticals, Inc.

Net loss of $6.5M ($0.18 basic EPS) vs $25.0M loss in Q1 2024; includes $5.2M non-cash gain on convertible loan.
Cash and equivalents $11.7M at March 31, 2025, up from $9.3M at Dec 31, 2024; 36.2M shares outstanding.
Topline results from Phase 1b/2a diSArm study of intravenous AP-SA02 for S. aureus bacteremia expected in first half 2025.
Received additional $4.65M non-dilutive DoD/MTEC funding to support AP-SA02 Phase 2 close-out and FDA end-of-Phase 2 meeting.
Entered $10.0M secured credit agreement with Innoviva; existing Innoviva credit agreements extended to March 12, 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.